Dynamic Advisor Solutions LLC lowered its stake in AbbVie Inc (NYSE:ABBV) by 34.0% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,377 shares of the company’s stock after selling 12,063 shares during the quarter. Dynamic Advisor Solutions LLC’s holdings in AbbVie were worth $1,884,000 at the end of the most recent reporting period.
Several other large investors also recently added to or reduced their stakes in the company. Prime Capital Investment Advisors LLC bought a new stake in AbbVie during the 4th quarter valued at $27,000. Penserra Capital Management LLC bought a new stake in AbbVie during the 4th quarter valued at $32,000. Larson Financial Group LLC bought a new stake in AbbVie during the 4th quarter valued at $37,000. Horrell Capital Management Inc. bought a new stake in AbbVie during the 4th quarter valued at $41,000. Finally, Capital Financial Planning LLC bought a new stake in AbbVie during the 4th quarter valued at $41,000. Institutional investors own 68.33% of the company’s stock.
NYSE ABBV opened at $78.57 on Thursday. The firm has a market capitalization of $115.56 billion, a PE ratio of 9.56, a PEG ratio of 1.60 and a beta of 1.10. AbbVie Inc has a 1 year low of $73.81 and a 1 year high of $100.23.
AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Thursday, April 25th. The company reported $2.14 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.06 by $0.08. The company had revenue of $7.83 billion for the quarter, compared to the consensus estimate of $7.81 billion. AbbVie had a net margin of 16.42% and a negative return on equity of 221.09%. The firm’s quarterly revenue was down 1.3% on a year-over-year basis. During the same period in the previous year, the firm earned $1.87 EPS. On average, research analysts expect that AbbVie Inc will post 8.81 earnings per share for the current year.
Several analysts have recently issued reports on ABBV shares. Barclays reiterated a “hold” rating and issued a $86.00 target price on shares of AbbVie in a research note on Thursday, February 14th. ValuEngine lowered shares of AbbVie from a “sell” rating to a “strong sell” rating in a research note on Friday, February 22nd. Argus lowered shares of AbbVie from a “buy” rating to a “hold” rating in a research note on Monday, March 25th. Zacks Investment Research lowered shares of AbbVie from a “hold” rating to a “sell” rating in a research note on Friday, April 5th. Finally, Credit Suisse Group set a $78.00 target price on shares of AbbVie and gave the stock a “sell” rating in a research note on Friday, April 26th. Four investment analysts have rated the stock with a sell rating, nine have issued a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $98.36.
In related news, VP Brian L. Durkin sold 475 shares of the business’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $79.69, for a total value of $37,852.75. Following the transaction, the vice president now directly owns 9,121 shares of the company’s stock, valued at approximately $726,852.49. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.08% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: This news story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2019/06/13/abbvie-inc-nyseabbv-shares-sold-by-dynamic-advisor-solutions-llc.html.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Featured Story: Why do company’s buyback their stock?
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.